These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 2910452)

  • 21. Imatinib mesylate (STI571) abrogates the resistance to doxorubicin in human K562 chronic myeloid leukemia cells by inhibition of BCR/ABL kinase-mediated DNA repair.
    Majsterek I; Sliwinski T; Poplawski T; Pytel D; Kowalski M; Slupianek A; Skorski T; Blasiak J
    Mutat Res; 2006 Jan; 603(1):74-82. PubMed ID: 16388976
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of erythroid differentiation by stem cell factor in K562 cells expressing the c-kit gene.
    Ogawa K; Tashima M; Toi T; Sawai H; Sawada H; Fujita J; Maruyama Y; Okuma M
    Exp Hematol; 1994 Jan; 22(1):45-51. PubMed ID: 7506674
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel oxime derivatives of radicicol induce erythroid differentiation associated with preferential G(1) phase accumulation against chronic myelogenous leukemia cells through destabilization of Bcr-Abl with Hsp90 complex.
    Shiotsu Y; Neckers LM; Wortman I; An WG; Schulte TW; Soga S; Murakata C; Tamaoki T; Akinaga S
    Blood; 2000 Sep; 96(6):2284-91. PubMed ID: 10979978
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Effect of combination of herbimycin A, an inhibitor of tyrosine kinase, and chemotherapeutic agents on apoptosis of K562 cells].
    Ren H; Chen S; Lu D
    Zhonghua Xue Ye Xue Za Zhi; 1997 May; 18(5):227-30. PubMed ID: 15622750
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells.
    Huang M; Dorsey JF; Epling-Burnette PK; Nimmanapalli R; Landowski TH; Mora LB; Niu G; Sinibaldi D; Bai F; Kraker A; Yu H; Moscinski L; Wei S; Djeu J; Dalton WS; Bhalla K; Loughran TP; Wu J; Jove R
    Oncogene; 2002 Dec; 21(57):8804-16. PubMed ID: 12483533
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hemin enhances the sensitivity of erythroleukemia cells to 1-beta-D-arabinofuranosylcytosine by both activation of deoxycytidine kinase and reduction of cytidine deaminase activity.
    Honma Y; Onozuka Y; Okabe-Kado J; Kasukabe T; Hozumi M
    Cancer Res; 1991 Sep; 51(17):4535-8. PubMed ID: 1873797
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice.
    Golas JM; Arndt K; Etienne C; Lucas J; Nardin D; Gibbons J; Frost P; Ye F; Boschelli DH; Boschelli F
    Cancer Res; 2003 Jan; 63(2):375-81. PubMed ID: 12543790
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Induction by some protein kinase inhibitors of differentiation of a mouse megakaryoblastic cell line established by coinfection with Abelson murine leukemia virus and recombinant SV40 retrovirus.
    Honma Y; Okabe-Kado J; Kasukabe T; Hozumi M; Kajigaya S; Suda T; Miura Y
    Cancer Res; 1991 Sep; 51(17):4649-55. PubMed ID: 1651810
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Geldanamycin and its analogue 17-allylamino-17-demethoxygeldanamycin lowers Bcr-Abl levels and induces apoptosis and differentiation of Bcr-Abl-positive human leukemic blasts.
    Nimmanapalli R; O'Bryan E; Bhalla K
    Cancer Res; 2001 Mar; 61(5):1799-804. PubMed ID: 11280726
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Altered queuine modification of transfer RNA involved in the differentiation of human K562 erythroleukemia cells in the presence of distinct differentiation inducers.
    Chen YL; Wu RT
    Cancer Res; 1994 Apr; 54(8):2192-8. PubMed ID: 7513611
    [TBL] [Abstract][Full Text] [Related]  

  • 31. AML1a but not AML1b inhibits erythroid differentiation induced by sodium butyrate and enhances the megakaryocytic differentiation of K562 leukemia cells.
    Niitsu N; Yamamoto-Yamaguchi Y; Miyoshi H; Shimizu K; Ohki M; Umeda M; Honma Y
    Cell Growth Differ; 1997 Mar; 8(3):319-26. PubMed ID: 9056674
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Human IL-3 receptor signaling: rapid induction of phosphatidylcholine hydrolysis is independent of protein kinase C but dependent on tyrosine phosphorylation in transfected NIH 3T3 cells.
    Rao P; Kitamura T; Miyajima A; Mufson RA
    J Immunol; 1995 Feb; 154(4):1664-74. PubMed ID: 7836750
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Involvement of a tyrosine kinase pathway in the growth-promoting effects of angiotensin II on aortic smooth muscle cells.
    Leduc I; Haddad P; Giasson E; Meloche S
    Mol Pharmacol; 1995 Oct; 48(4):582-92. PubMed ID: 7476882
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.
    Koch A; Scherr M; Breyer B; Mancini A; Kardinal C; Battmer K; Eder M; Tamura T
    Oncogene; 2008 Aug; 27(34):4678-89. PubMed ID: 18427551
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of ERK activation in growth and erythroid differentiation of K562 cells.
    Woessmann W; Mivechi NF
    Exp Cell Res; 2001 Apr; 264(2):193-200. PubMed ID: 11262176
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bcr-Abl-mediated resistance to apoptosis is independent of constant tyrosine-kinase activity.
    Bueno-da-Silva AE; Brumatti G; Russo FO; Green DR; Amarante-Mendes GP
    Cell Death Differ; 2003 May; 10(5):592-8. PubMed ID: 12728257
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tyrphostin induced growth inhibition: correlation with effect on p210bcr-abl autokinase activity in K562 chronic myelogenous leukemia.
    Kaur G; Gazit A; Levitzki A; Stowe E; Cooney DA; Sausville EA
    Anticancer Drugs; 1994 Apr; 5(2):213-22. PubMed ID: 8049505
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Proteasome inhibition leads to significant reduction of Bcr-Abl expression and subsequent induction of apoptosis in K562 human chronic myelogenous leukemia cells.
    Dou QP; McGuire TF; Peng Y; An B
    J Pharmacol Exp Ther; 1999 May; 289(2):781-90. PubMed ID: 10215653
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of herbimycin A, an inhibitor of tyrosine kinase, on protein tyrosine kinase activity and phosphotyrosyl proteins of Ph1-positive leukemia cells.
    Okabe M; Kawamura K; Miyagishima T; Itaya T; Goodwyn D; Shoji M; Vogler WR; Sakurada K; Uehara M; Miyazaki T
    Leuk Res; 1994 Mar; 18(3):213-20. PubMed ID: 7511193
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inactivation of ERK accelerates erythroid differentiation of K562 cells induced by herbimycin A and STI571 while activation of MEK1 interferes with it.
    Kawano T; Horiguchi-Yamada J; Iwase S; Furukawa Y; Kano Y; Yamada H
    Mol Cell Biochem; 2004 Mar; 258(1-2):25-33. PubMed ID: 15030167
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.